About The Valve Wire
Our Mission
The Valve Wire provides daily, balanced analysis of transcatheter valve technology — covering aortic (TAVR/TAVI), mitral (MitraClip, PASCAL, TMVR), and tricuspid (TriClip, TTVR) therapies. We aggregate research from academic, regulatory, financial, and social sources, then synthesize it into an accessible daily digest.
Our audience includes cardiac surgeons, interventional cardiologists, trainees, informed patients, industry stakeholders, and regulatory agencies. Whether you are in the cath lab, the OR, the boardroom, or the waiting room, The Valve Wire keeps you informed.
Editorial Stance
Many structural heart technologies have gotten ahead of the science and clinical guidelines. We are committed to presenting balanced, circumspect analysis:
- •We always present competing arguments for and against favorable findings
- •We flag study limitations: non-randomized designs, industry sponsorship, short follow-up, small samples
- •When reporting favorable transcatheter outcomes, we note durability concerns, patient selection biases, and surgical alternatives
- •Our tone is expert skepticism — enthusiastic about real advances but always questioning
AI Disclosure
The Valve Wire uses artificial intelligence to aggregate and synthesize content from peer-reviewed journals, regulatory databases, clinical trial registries, financial data, and news sources. The daily digest and weekly podcast are AI-generated using Claude (Anthropic) for text synthesis and editorial analysis.
While we strive for accuracy and balance, AI-synthesized content should not be considered medical advice. Always consult primary sources and clinical guidelines for patient care decisions.
Contact
Questions, corrections, or feedback? Reach us at nolan.beckett@pm.me